Literature DB >> 9188646

Subunit-specific mutagenesis of the cysteine 280 residue of the reverse transcriptase of human immunodeficiency virus type 1: effects on sensitivity to a specific inhibitor of the RNase H activity.

S Loya1, H Q Gao, O Avidan, P L Boyer, S H Hughes, A Hizi.   

Abstract

Treatment of human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT) with N-ethylmaleimide (NEM) selectively inhibits the RNase H activity. The cysteine residue at position 280 (C280) is the target for NEM; HIV-1 RT carrying the mutation C280S is resistant to NEM. Since HIV-1 RT is composed of two related subunits (p66 and p51) that play distinct roles, we asked whether the C280 in p51 or the C280 in p66 is responsible for the sensitivity of the enzyme to NEM. HIV-1 RT versions were prepared that had one mutant and one wild-type subunit. When these chimeric enzymes were tested, both the p51 and p66 subunits were found to contribute to the sensitivity of the enzyme to NEM. The implications of these results are discussed in the context of the structure of the enzyme.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9188646      PMCID: PMC191814          DOI: 10.1128/JVI.71.7.5668-5672.1997

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

Review 1.  Retroviral reverse transcriptase: synthesis, structure, and function.

Authors:  S P Goff
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

Review 2.  HIV-1 reverse transcriptase: structure predictions for the polymerase domain.

Authors:  A M Barber; A Hizi; J V Maizel; S H Hughes
Journal:  AIDS Res Hum Retroviruses       Date:  1990-09       Impact factor: 2.205

3.  Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV.

Authors:  F di Marzo Veronese; T D Copeland; A L DeVico; R Rahman; S Oroszlan; R C Gallo; M G Sarngadharan
Journal:  Science       Date:  1986-03-14       Impact factor: 47.728

4.  Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography.

Authors:  S F Le Grice; F Grüninger-Leitch
Journal:  Eur J Biochem       Date:  1990-01-26

5.  Illimaquinone, a selective inhibitor of the RNase H activity of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  S Loya; R Tal; Y Kashman; A Hizi
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

6.  Catalytic properties of the reverse transcriptases of human immunodeficiency viruses type 1 and type 2.

Authors:  A Hizi; R Tal; M Shaharabany; S Loya
Journal:  J Biol Chem       Date:  1991-04-05       Impact factor: 5.157

7.  The effects of cysteine mutations on the reverse transcriptases of human immunodeficiency virus types 1 and 2.

Authors:  A Hizi; M Shaharabany; R Tal; S H Hughes
Journal:  J Biol Chem       Date:  1992-01-15       Impact factor: 5.157

8.  Structure of HIV-1 reverse transcriptase/DNA complex at 7 A resolution showing active site locations.

Authors:  E Arnold; A Jacobo-Molina; R G Nanni; R L Williams; X Lu; J Ding; A D Clark; A Zhang; A L Ferris; P Clark
Journal:  Nature       Date:  1992-05-07       Impact factor: 49.962

Review 9.  Nonnucleoside inhibitors of HIV-1 reverse transcriptase: nevirapine as a prototype drug.

Authors:  P M Grob; J C Wu; K A Cohen; R H Ingraham; C K Shih; K D Hargrave; T L McTague; V J Merluzzi
Journal:  AIDS Res Hum Retroviruses       Date:  1992-02       Impact factor: 2.205

10.  Structural characterization of reverse transcriptase and endonuclease polypeptides of the acquired immunodeficiency syndrome retrovirus.

Authors:  M M Lightfoote; J E Coligan; T M Folks; A S Fauci; M A Martin; S Venkatesan
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

View more
  8 in total

1.  Unique progressive cleavage mechanism of HIV reverse transcriptase RNase H.

Authors:  M Wisniewski; M Balakrishnan; C Palaniappan; P J Fay; R A Bambara
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

2.  The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities.

Authors:  P Gerondelis; R H Archer; C Palaniappan; R C Reichman; P J Fay; R A Bambara; L M Demeter
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

3.  Selection of optimal polypurine tract region sequences during Moloney murine leukemia virus replication.

Authors:  N D Robson; A Telesnitsky
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  Analysis of human immunodeficiency virus type 1 reverse transcriptase subunit structure/function in the context of infectious virions and human target cells.

Authors:  Alok Mulky; John C Kappes
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

5.  Subunit-specific analysis of the human immunodeficiency virus type 1 reverse transcriptase in vivo.

Authors:  Alok Mulky; Stefan G Sarafianos; Edward Arnold; Xiaoyun Wu; John C Kappes
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

6.  Effects of 3' untranslated region mutations on plus-strand priming during moloney murine leukemia virus replication.

Authors:  N D Robson; A Telesnitsky
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

7.  Insertion of a small peptide of six amino acids into the beta7-beta8 loop of the p51 subunit of HIV-1 reverse transcriptase perturbs the heterodimer and affects its activities.

Authors:  Pradeep K Pandey; Neerja Kaushik; Kamalendra Singh; Bechan Sharma; Alok K Upadhyay; Suriender Kumar; Dylan Harris; Virendra N Pandey
Journal:  BMC Biochem       Date:  2002-06-18       Impact factor: 4.059

8.  Global Conformational Dynamics of HIV-1 Reverse Transcriptase Bound to Non-Nucleoside Inhibitors.

Authors:  David W Wright; Benjamin A Hall; Paul Kellam; Peter V Coveney
Journal:  Biology (Basel)       Date:  2012-07-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.